(TSX:DPM),(AUST:DPM.AX), TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — DPM Metals Inc. (TSX: DPM, ASX: DPM) (ARBN: 689370894) (“DPM” or the “Company”) announced its operating and financial results for the third quarter and first nine months ended September 30, 2025. Highlights (Unless otherwise stated, all monetary figures in this news release are expressed in U.S. dollars, […]

(NYSE:TRC), TEJON RANCH, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Tejon Ranch Co. (the “Company”) (NYSE:TRC), a diversified real estate development and agriculture company, today issued a public letter from President and Chief Executive Officer Matthew Walker to their shareholders, ahead of the Company's Investor Engagement Event, being held tomorrow at the New York Stock

(TSX:PEY), CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (“Peyto” or the “Company”) is pleased to report operating and financial results for the third quarter of 2025 and a preliminary capital budget for 2026. Highlights: Peyto reported $198.9 million in funds from operations1,2 (“FFO”), or $0.98/diluted share, and generated $69.1

(NASDAQ:SABS),(NASDAQ:SABSW), Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patients Multiple SAFEGUARD trial sites activated; on-track to dose first patient by year-end Recent data presented at EASD and IPSAD provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying, immunotherapeutic approach to redefine treatment of Stage 3 T1D

(TSX:EGLX),(Boerse Frankfurt – Freiverkehr:2AV.F), Adjusted EBITDA from continuing operations of $1.2 million for the nine months ended September 30, 2025, compared to a loss of $0.1 million in the year ago period Completed sale of Direct Sales Media Business and related creative assets in Q3, resulting in a gain on sale of subsidiaries and assets

(TSX-V:OML),(OTC US:OLNCF),(OTCQX:OLNCF), TSXV: OML OTCQX: OLNCF LOS ANGELES, CALIFORNIA, Nov. 13, 2025 (GLOBE NEWSWIRE) — Omni-Lite Industries Canada, Inc. (the “Company” or “Omni-Lite”; TSXV: OML), a designer and manufacturer of precision high performance components for aerospace & defense, transportation, and communication applications is pleased to announce the results of its Annual General Meeting of shareholders

(TSX:EPRX),(NASDAQ:EPRX), The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far. In Cohort 6, a durable clinical symptom response was observed 52 weeks after a single administration of EP-104GI. All

(NASDAQ:SDST),(NASDAQ:SDSTW), GREENWICH, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) — Stardust Power Inc. (“Stardust Power” or the “Company”) (Nasdaq: SDST), an American developer of battery-grade lithium carbonate, today announced its results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Updates and Subsequent Events Operational highlights for the third quarter of 2025 include:

(TSX:APS),(OTC US:APTOF),(Other OTC:APTOF), Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now Being Treated at 160 mg Dose of Tuspetinib SAN DIEGO and TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or

(TSX:STN),(NYSE:STN), Highlights Net revenue of $1.7 billion, an increase of 11.8% compared to Q3 2024 Adjusted EBITDA1 increase of 17.8% to $323.4 million and adjusted EBITDA margin1 of 19.0%, a 100 basis point increase over Q3 2024 Diluted EPS of $1.32 and adjusted EPS1 of $1.53, up 46.7% and 17.7%, respectively, compared to Q3 2024